Staedtisches Klinikum Dresden — Clinical Trial Site

30 Registered trials

13 Currently recruiting

Organisation

Staedtisches Klinikum Dresden

Location

Dresden, Germany

Identifier

ORG-100048550

Address

Friedrichstrasse 41, Friedrichstadt, 01067, Germany

Departments

#1809:1. Medizinische Klinik
1. Medizibische Klinik
1. Medizinische Klinik
1. Medizinische Klinik Rheumatologie, Nephrologie, Klinische Immunologie
2. Medizinische Klinik
2nd Medical Clinic
2nd Medical Department
4. Medizinische Klinik
4. Medizinische Klinik (Hämatologie, internistische Onkologie und Palliativmedizin)
Department for Dermatology and Allergology
I. medizinische Klinik - Rheumatologie
II. Medizinische Klinik
Internal Medicine
Klinik für Neurologie
N/A
NA
Onkologisches Zentrum
Rheumatology
Städtisches Klinikum Dresden
Studienzentrale

Clinical trials at this site (30)

Search interface

A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Recruiting

2025-523579-47-00 moderate to severe rheumatoid arthritis (RA) 4 2026-06-19
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or… Recruiting

2025-521034-28-00 Moderate to Severe Rheumatoid Arthritis (RA) 4 2025-12-05
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
A study of the efficacy and safety of Belimumab in adults with interstitial lung disease associated with connective tissue disease. Recruiting

2024-513018-36-00 Lung Diseases, Interstitial 5 2025-03-06
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Gastroesophageal Adenocarcinoma 4 2025-12-16
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Venous leg ulcer 5 2025-10-20
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Acute Myocardial Infarction 5 2025-06-12
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting

2023-509632-26-00 Recurrent or Metastatic Solid Tumors (endometrial cance 9 2025-02-11
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Moderate-to-severe Systemic Lupus Erythematosus (SLE) 10 2021-10-22
PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll… Ended

2024-511321-54-00 intermediate-high-risk acute pulmonary embolism 5 2021-08-04
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended

2023-503628-22-00 Lupus Nephritis (LN) 5 2020-07-16
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended

2023-508736-62-00 Heart failure (HF) with reduced ejection fraction (HFrE 4 2024-08-08
A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti… Ended

2023-508737-13-00 chronic heart failure 4 2024-08-08
A study to test whether BI 765845 helps people who have had a heart attack Ended

2022-502788-39-00 acute myocardial infarction 4 2023-11-27
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18